论文部分内容阅读
阿克拉霉素(Aclacinomycin,简称ACM)为第二代蒽环类抗肿瘤抗生素,1975年由日本学者梅泽滨夫首先报道,ACM加利利链霉菌(Streptomyces galilaeus)MA144Ml株培养物中分离得到,其主要抗瘤活性成份为ACM A和ACM B.国内四川抗菌素工业研究所1979年也报道从加利利链霉菌思文变种(S.galilaeus var.siwenensis)77-3082株培养物中分离到ACM A和ACM B.十多年来,国外对ACM A进行了大量研究.目前,临床研究正在深入,并已有商品上市.国内在开发ACM A的同时,也对ACM B进行了研究,但主要研究ACM A,其临床前的试验工作已基本结束,
Aclacinomycin (ACM) is the second generation anthracycline antitumor antibiotic. In 1975, it was first reported by Japanese scholar Mei Zebinfu that the ACM strain Streptomyces galilaeus MA144Ml was isolated , Its main anti-tumor active ingredients ACM A and ACM B. Domestic antibiotics industry in Sichuan Institute also reported 1979 from S. Galilaeus var. Siwenensis 77-3082 strain isolated ACM A and ACM B. For more than a decade, a large number of studies have been conducted abroad on ACM A. At present, clinical studies are in-depth and have been listed on the market.At the same time ACM A was developed in China, ACM B was also studied, but mainly Research ACM A, its preclinical work has been basically completed,